Leishmaniasis: Efflux pumps and chemoresistance

International Journal of Antimicrobial Agents

Volumn 22, Issue 3, 2003, Pages 352-357

  Leandro, Clara ^a   Campino, Lenea ^b  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Chemoresistance; Efflux pumps; Inhibitors; Leishmania

Indexed keywords

ABC TRANSPORTER; ALLOPURINOL; ALLYLAMINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIMONY DERIVATIVE; ARSENIC TRIOXIDE; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; EDELFOSINE; FLUCONAZOLE; FOLIC ACID DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METHOTREXATE; MILTEFOSINE; MULTIDRUG RESISTANCE PROTEIN; PAROMOMYCIN; PENTAMIDINE; PENTOSTAN; PUROMYCIN; PYRROLE DERIVATIVE; QUINIDINE; STIBOGLUCONATE SODIUM; TERBINAFINE; THIORIDAZINE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TRANSPORT; GENE AMPLIFICATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; SKIN LEISHMANIASIS; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

EID: 0041331783     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00211-5     Document Type: Article

References (80)

1. Desjeux P. Worldwide increasing risk factors for leishmaniasis. Med. Microbiol. Immunol. (Berlin). 190:2001;77-79.
2. Herwaldt B.L., Berman J.D. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 46:1992;296-306.
3. Delgado J., Macias J., Pineda J.A., Corzo J.E., Gonzalez-Moreno M.P., de la Rosa R., Sanchez-Quijano A., Leal M., Lissen E. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am. J. Trop. Med. Hyg. 61:1999;766-769.
4. Faraut-Gambarelli F., Piarroux R., Deniau M., Giusiano B., Marty P., Michel G., Faugere B., Dumon H. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 41:1997;827-830.
5. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., Sacks D. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180:1999;564-567.
6. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health. 6:2001;849-854.
7. Sundar S., Pai K., Kumar R., Pathak-Tripathi K., Gam A.A., Ray M., Kenney R.T. Resistance to treatment in kala-azar: speciation of isolates from northeast India. Am. J. Trop. Med. Hyg. 65:2001;193-196.
8. Gramiccia M., Gradoni L., Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann. Trop. Med. Parasitol. 86:1992;613-620.
9. Grögl M., Oduola A.M., Cordero L.D., Kyle D.E. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure. Exp. Parasitol. 69:1989;78-90.
10. Ephros M., Waldman E., Zilberstein D. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob. Agents Chemother. 41:1997;1064-1068.
11. Sereno D., Guilvard E., Maquaire S., Cavaleyra M., Holzmuller P., Ouaissi A., Lemesre J.L. Experimental studies on the evolution of antimony-resistant phenotype during the in vitro life cycle of Leishmania infantum: implications for the spread of chemoresistance in endemic areas. Acta Trop. 80:2001;195-205.
12. Becker I., Volkow P., Velasco-Castrejon O., Salaiza-Suazo N., Berzunza-Cruz M., Dominguez J.S., Morales-Vargas A., Ruiz-Remigio A., Perez-Montfort R. The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. Parasitol. Res. 85:1999;165-170.
13. Basselin M., Lawrence F., Robert-Gero M. Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes. Biochem. J. 315:1996;631-634.
14. Basselin M., Lawrence F., Robert-Gero M. Altered transport properties of pentamidine-resistant L. donovani and L. amazonensis promastigotes. Parasitol. Res. 83:1997;413-418.
15. Nacher M., Carme B., Sainte Marie D., Couppie P., Clyti E., Guibert P., Pradinaud R. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol. 95:2001;331-336.
16. el-On J., Halevy S., Grunwald M.H., Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J. Am. Acad. Dermatol. 27:1992;227-231.
17. Davidson R.N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G.B., Pempinello R., Scott S., Raimondi F., Cascio A., et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q. J. Med. 87:1994;75-81.
18. Jha T.K., Sundar S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A., Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. New Engl. J. Med. 341:1999;1795-1800.
19. Saenz R.E., Paz H.M., Johnson C.M., Marr J.J., Nelson D.J., Pattishall K.H., Rogers M.D. Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside. J. Infect. Dis. 160:1989;153-158.
20. Dogra J., Aneja N., Lal B.B., Mishra S.N. Cutaneous leishmaniasis in India. Clinical experience with itraconazole (R51 211 Janssen). Int. J. Dermatol. 29:1990;661-662.
21. Thakur C.P., Kanyok T.P., Pandey A.K., Sinha G.P., Zaniewski A.E., Houlihan H.H., Olliaro P. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94:2000;429-431.
22. Maarouf M., Lawrence F., Brown S., Robert-Gero M. Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes. Parasitol. Res. 83:1997;198-202.
23. Fong D., Chan M.M., Rodriguez R., Gately L.J., Berman J.D., Grogl M. Paromomycin resistance in Leishmania tropica: lack of correlation with mutation in the small subunit ribosomal RNA gene. Am. J. Trop. Med. Hyg. 51:1994;758-766.
24. Maarouf M., Adeline M.T., Solignac M., Vautrin D., Robert-Gero M. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite. 5:1998;167-173.
25. Ramos H., Saint-Pierre-Chazalet M., Bolard J., Cohen B.E. Effect of ketoconazole on lethal action of amphotericin B on Leishmania mexicana promastigotes. Antimicrob. Agents Chemother. 38:1994;1079-1084.
26. Azas N., Di Giorgio C., Delmas F., Gasquet M., Timon-David P. No evidence of oxidant events in amphotericin B cytotoxicity versus L. infantum promastigotes. Parasite. 8:2001;335-341.
27. Zilberstein D., Ephros M. Clinical and laboratory aspects of Leishmania chemotherapy in the era of drug resistance. Farrell J.P. Leishmania. 2002;193 Kluwer Academic Publishers, Massachusetts.
28. Freire M., Badaro F., Avelar M.E., Luz K., Nakatani M.S., Teixeira R., Martins Netto E., Badaro R. Efficacy and Tolerability of Liposomal Amphotericin B (Ambisome) in the treatment of visceral leishmaniasis in Brazil. Braz. J. Infect. Dis. 1:1997;230-240.
29. Thakur C.P., Narain S., Kumar N., Hassan S.M., Jha D.K., Kumar A. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann. Trop. Med. Parasitol. 91:1997;611-616.
30. Koss T., Bagheri B., Zeana C., Romagnoli M.F., Grossman M.E. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J. Am. Acad. Dermatol. 46:2002;945-947.
31. Rodero L., Cuenca-Estrella M., Cordoba S., Cahn P., Davel G., Kaufman S., Guelfand L., Rodriguez-Tudela J.L. Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii. J. Clin. Microbiol. 40:2002;2266-2269.
32. Mbongo N., Loiseau P.M., Billion M.A., Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42:1998;352-357.
33. Bahamdan K.A., Tallab T.M., Johargi H., Nourad M.M., Ibrahim K., el Sherbini A.H., Karkashan E., Khare A.K., Nauri M.M. Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study. Int. J. Dermatol. 36:1997;59-60.
34. Salmanpour R., Handjani F., Nouhpisheh M.K. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J. Dermatol. Treat. 12:2001;159-162.
35. Alrajhi A.A., Ibrahim E.A., De Vol E.B., Khairat M., Faris R.M., Maguire J.H. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. New Engl. J. Med. 346:2002;891-895.
36. Urbina J.A. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology. 114:(Suppl.):1997;S91-S99.
37. Sundar S., Singh V.P., Agrawal N.K., Gibbs D.L., Murray H.W. Treatment of kala-azar with oral fluconazole. Lancet. 348:1996;614.
38. Olliaro P., Bryceson A. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol. Today. 9:1993;323-328.
39. Velez I., Agudelo S., Hendrickx E., Puerta J., Grogl M., Modabber F., Berman J. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann. Intern. Med. 12:1997;232-236.
40. Denerolle P., Bourdoiseau G. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). J. Vet. Intern. Med. 13:1999;413-415.
41. Koutinas A.F., Saridomichelakis M.N., Mylonakis M.E., Leontides L., Polizopoulou Z., Billinis C., Argyriadis D., Diakou N., Papadopoulos O. A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vet. Parasitol. 98:2001;247-261.
42. el-On J., Rubinstein N., Kernbaum S., Schnur L.F. in vitro and in vivo anti-leishmanial activity of chlorpromazine alone and combined with N-meglumine antimonate. Ann. Trop. Med. Parasitol. 80:1986;509-517.
43. Zilberstein D., Liveanu V., Gepstein A. Tricyclic drugs reduce proton motive force in Leishmania donovani promastigotes. Biochem. Pharmacol. 39:1990;935-940.
44. Brendle J.J., Outlaw A., Kumar A., Boykin D.W., Patrick D.A., Tidwell R.R., Werbovetz K.A. Antileishmanial activities of several classes of aromatic dications. Antimicrob. Agents Chemother. 46:2002;797-807.
45. Desjeux P., Karbwang J. Miltefosine - 1200 patients in phase IV trial in India. TDRnews. 69:2002;12.
46. Ouellette M., Fase-Fowler F., Borst P. The amplified H circle of methotrexate-resistant Leishmania tarentolae contains a novel P-glycoprotein gene. EMBO J. 9:1990;1027-1033.
47. Higgins C.F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8:1992;67-113.
48. Légaré D., Hettema E., Ouellette M. The P-glycoprotein-related gene family in Leishmania. Mol. Biochem. Parasitol. 68:1994;81-91.
49. Callahan H.L., Beverley S.M. Heavy metal resistance: a new role for P-glycoproteins in Leishmania. J. Biol. Chem. 266:1991;18427-18430.
50. Papadopoulou B., Roy G., Dey S., Rosen B.P., Ouellette M. Contribution of the Leishmania P-glycoprotein-related gene ltpgpA to oxyanion resistance. J. Biol. Chem. 269:1994;11980-11986.
51. Légaré D., Papadopoulou B., Roy G., Mukhopadhyay R., Haimeur A., Dey S., Grondin K., Brochu C., Rosen B.P., Ouellette M. Efflux systems and increased trypanothione levels in arsenite-resistant Leishmania. Exp. Parasitol. 87:1997;275-282.
52. Ouellette M., Hettema E., Wust D., Fase-Fowler F., Borst P. Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania. EMBO J. 10:1991;1009-1016.
53. Essodaigui M., Frezard F., Moreira E.S., Dagger F., Garnier-Suillerot A. Energy-dependent efflux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps. Mol. Biochem. Parasitol. 100:1999;73-84.
54. Henderson D.M., Sifri C.D., Rodgers M., Wirth D.F., Hendrickson N., Ullman B. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene. Mol. Cell. Biol. 12:1992;2855-2865.
55. Chow L.M., Wong A.K., Ullman B., Wirth D.F. Cloning and functional analysis of an extrachromosomally amplified multidrug resistance-like gene in Leishmania enriettii. Mol. Biochem. Parasitol. 60:1993;195-208.
56. Gueiros-Filho F.J., Viola J.P., Gomes F.C., Farina M., Lins U., Bertho A.L., Wirth D.F., Lopes U.G. Leishmania amazonensis: multidrug resistance in vinblastine-resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr1 gene. Exp. Parasitol. 81:1995;480-490.
57. Chiquero M.J., Perez-Victoria J.M., O'Valle F., Gonzalez-Ros J.M., del Moral R.G., Ferragut J.A., Castanys S., Gamarro F. Altered drug membrane permeability in a multidrug-resistant Leishmania tropica line. Biochem. Pharmacol. 55:1998;131-139.
58. Perez-Victoria J.M., Parodi-Talice A., Torres C., Gamarro F., Castanys S. ABC transporters in the protozoan parasite Leishmania. Int. Microbiol. 4:2001;159-166.
59. Perez-Victoria J.M., Perez-Victoria F.J., Parodi-Talice A., Jimenez I.A., Ravelo A.G., Castanys S., Gamarro F. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. 45:2001;2468-2474.
60. Frézard F., Demicheli C., Ferreira C.S., Costa M.A. Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob. Agents Chemother. 45:2001;913-916.
61. Shaked-Mishan P., Ulrich N., Ephros M., Zilberstein D. Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 276:2001;3971-3976.
62. De Stasio E.A., Moazed D., Noller H.F., Dahlberg A.E. Mutations in 16S ribosomal RNA disrupt antibiotic-RNA interactions. EMBO J. 8:1989;1213-1216.
63. Nelson D.J., LaFon S.W., Tuttle J.V., Miller W.H., Miller R.L., Krenitsky T.A., Elion G.B., Berens R.L., Marr J.J. Allopurinol ribonucleoside as an antileishmanial agent. Biological effects, metabolism, and enzymatic phosphorylation. J. Biol. Chem. 254:1979;11544-11549.
64. Ellenberger T.E., Beverley S.M. Reductions in methotrexate and folate influx in methotrexate-resistant lines of Leishmania major are independent of R or H region amplification. J. Biol. Chem. 262:1987;13501-13506.
65. Detke S., Chaudhuri G., Kink J.A., Chang K.P. DNA amplification in tunicamycin-resistant Leishmania mexicana. Multicopies of a single 63-kb supercoiled molecule and their expression. J. Biol. Chem. 263:1988;3418-3424.
66. Katakura K., Peng Y., Pithawalla R., Detke S., Chang K.P. Tunicamycin-resistant variants from five species of Leishmania contain amplified DNA in extrachromosomal circles of different sizes with a transcriptionally active homologous region. Mol. Biochem. Parasitol. 44:1991;233-243.
67. Kundig C., Leblanc E., Papadopoulou B., Ouellette M. Role of the locus and of the resistance gene on gene amplification frequency in methotrexate resistant Leishmania tarentolae. Nucleic Acids Res. 27:1999;3653-3659.
68. Kaur K., Coons T., Emmett K., Ullman B. Methotrexate-resistant Leishmania donovani genetically deficient in the folate-methotrexate transporter. J. Biol. Chem. 263:1988;7020-7028.
69. Stein W.D. Reversers of the multidrug resistance transporter P-glycoprotein. Curr. Opin. Invest. Drugs. 3:2002;812-817.
70. Perez-Victoria J.M., Perez-Victoria F.J., Conseil G., Maitrejean M., Comte G., Barron D., Di Pietro A., Castanys S., Gamarro F. High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin. Antimicrob. Agents Chemother. 45:(2):2001;439-446.
71. Haimeur A., Guimond C., Pilote S., Mukhopadhyay R., Rosen B.P., Poulin R., Ouellette M. Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol. Microbiol. 34:1999;726-735.
72. Ford J.M., Prozialeck W.C., Hait W.N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 35:1989;105-115.
73. Pearce H.L., Winter M.A., Beck W.T. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv. Enzyme Regul. 30:1990;357-373.
74. Werbovetz K.A., Lehnert E.K., Macdonald T.L., Pearson R.D. Cytotoxicity of acridine compounds for Leishmania promastigotes in vitro. Antimicrob. Agents Chemother. 36:1992;495-497.
75. Pearson R.D., Manian A.A., Harcus J.L., Hall D., Hewlett E.L. Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donovani. Science. 217:1982;369-371.
76. el-On J., Rubinstein N., Kernbaum S., Schnur L.F. in vitro and in vivo anti-leishmanial activity of chlorpromazine alone and combined with N-meglumine antimonate. Ann. Trop. Med. Parasitol. 80:1986;509-517.
77. Amaral L., Viveiros M., Kristiansen J.E. Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Trop. Med. Int. Health. 6:2001;1016-1022.
78. Ordway D., Viveiros M., Leandro C., Arroz M.J., Amaral L. Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. Int. J. Antimicrob. Agents. 20:2002;34-43.
79. Ordway D., Viveiros M., Leandro C., Bettencourt R., Almeida J., Martins M., Kristiansen J.E., Molnar J., Amaral L. Clinical concentrations of thioridazine kill intracellular multidrug resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:2003;917-922.
80. Viveiros M., Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents. 17:2001;225-228.